Chamber and committees

While the Scottish Government are responsible for the strategic direction of the NHS, territorial Health Boards and Integration Authorities are responsible for delivering services in their areas, including the amount spent on each of the service areas delivered by the Primary Care Improvement Fund (PCIF). Integrated Authorities must work closely with local communities and other stakeholders to ensure that Primary Care Improvement Plans address specific local challenges and population needs while taking into account the guidance in the GP contract and accompanying MoUs as well as amended regulations.

The Scottish Government recognises the impact of these global medicine shortages on people living with cystic fibrosis. The supply of medicines and associated legislation are a reserved matter for the UK Government, and we continue to engage with them on this supply issue and other medicine shortages. The Chief Pharmaceutical Officer (CPO) for Scotland is a member of a UK-wide Medicines Shortage Response Group (MSRG), set up to identify and co-ordinate responses to medicines shortages across the UK and provide advice to prescribers on alternative therapeutic options.

In May, the Scottish Government issued a Medicine Supply Alert Notice (MSAN) and a National Patient Safety Alert (NatPSA) which outline actions to be taken by prescribers, who are best-placed to determine the impact of this shortage on each individual person, and offer an alternative treatment, where appropriate. We also issued a Serious Shortage Protocol (SSP) for Creon ® 25000 gastro-resistant capsules which allows community pharmacists to restrict the total quantity of Creon ® supplied to one month’s supply to help conserve stocks of Creon ® .

As previously advised in answer to question S6W-26346 on 9 April 2024, the current phase of Clyde Metro is being led by Strathclyde Partnership for Transport, working alongside Glasgow City Council and with Transport Scotland providing support in a project assurance role.

SPT have recently appointed consultants to undertake some preliminary work, with procurement of a framework for multi-disciplinary consultancy services for later phases of the case for investment currently ongoing.

As such, Transport Scotland is not promoting a policy aimed at increasing population density in the vicinity of railway stations in Glasgow.

All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

NatureScot holds data on the type of roosts recorded by bat workers during visits to homes, including the number of bats present, and whether the roost was retained or excluded under licence.

In 2023, in Bats in Houses, a total of 74 bat roosts were excluded from properties across Scotland, following householder requests to do so due to Health & Safety requirements:

As this is an operational matter for Scottish Water, and the Scottish Government does not hold this information, I have asked them to respond. Their reply is as follows:

Scottish Water is currently developing its Long Term Strategy, due for publication in January 2025, which will include the investment requirements for addressing the forecast supply-demand deficits through demand reduction activities, increased connectivity between supply systems and potentially new water sources.

Scottish Water is also working on a zonal model which will inform the strategic choices for managing their supply-demand balance. Scottish Water is in the middle of the detailed planning activities and will be in a position to respond to the specifics of this query by the end of December 2024/early in 2025.

There are three licensed Cannabis Based Products for Medicinal use (CBPMs) available on the NHS in Scotland to treat specific conditions. These are:

• nabilone, a synthetic cannabinoid, as an add-on treatment for adults with chemotherapy-induced nausea and vomiting;
• Sativex®, a combination of delta-9-tetrahydrocannabinol and cannabidiol for moderate to severe spasticity in adults with multiple sclerosis;
• and Epidyolex®, a cannabidiol for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex (TSC)

The decision on whether to make a licensed medicine routinely available on the NHS in Scotland is made by healthcare professionals and other experts who make up the Scottish Medicines Consortium (SMC), following an application by the manufacturer. This is independent of Scottish Ministers. If a medicine is recommended for use,- Health Boards’ local Area Drug and Therapeutic Committees will consider and decide whether to include it in their prescribing formulary.

Clinical guidance does not recommend the prescribing of unlicensed CBPMs, other than in clinical trials. The biggest barrier to the prescribing of other CBPMs on the NHS is that most products remain unlicensed with a limited, or non-existent, peer-reviewed clinical evidence base for their use.

The Scottish Government is aware that supplies of various ADHD medicines continue to be intermittent. At present, market data and information provided by the UK Government indicates that some of these supply issues will continue into Autumn 2024. Scottish Government officials continue to monitor the situation for any further developments and are maintaining a close dialogue with all Health Boards to help manage these medicine supply disruptions and provide support when needed.

The supply of medicines and associated legislation are a reserved matter for the UK Government, and we continue to engage with them on this supply issue and other medicine shortages. The Chief Pharmaceutical Officer for Scotland is a member of a UK-wide Medicines Shortage Response Group, set up to identify and co-ordinate responses to medicines shortages across the UK and provide advice to prescribers on alternative therapeutic options.

The UK Government’s Department of Health and Social Care, on behalf of all four nations, regularly meets with the manufacturers of ADHD medicines to discuss their supply chains challenges and any issues where they may require assistance, including providing an overview of current and forecasted demand to assist manufacturers with planning to increase production forecasts. T he Scottish Government has not had any separate engagement with the manufacturers of ADHD medicines.

All bat species found in Scotland are classed as European protected species. They receive the highest level of species protection under the Conservation (Natural Habitats, &c.) Regulations 1994.

This protection also extends to bat roosts. As bats return to the same places every year, a bat roost is protected even if no bats are present. Any action taken which might disturb or damage a bat roost requires a licence from NatureScot.

NatureScot bat workers and Licensing staff advise residents on bat species protection and how to manage the bat roosts within their homes in line with this protection through the Bats in Houses helpline or, for more complex cases, a home visit. NatureScot staff encourage residents in the first instance to retain these roosts, though in some circumstances they need to be excluded under licence because of the public health issue they can pose to residents. The licence to exclude bats contains conditions for the actions to safeguard the bats during the exclusion.

The Marine Fund Scotland (MFS) has paid £11.63m to applicants who were awarded total funding of £14m in 2023-24. Individual awards are published here - https://www.gov.scot/publications/marine-fund-scotland-grants-awarded/ . The Scottish Government publishes all payments over £25k here - https://www.gov.scot/collections/government-spend-over-gbp25000-monthly-reports/ .

The remaining £2.37m funding supported data collection on stocks in the North Sea and the West of Scotland. This information is combined with data from other European nations who fish in these waters and is then considered by the International Council for Exploration of the Seas (ICES).

The Young Person’s Guarantee was introduced in response to the Covid-19 pandemic as a measure to prevent long-term adverse impacts for young people in the labour market. It contained a number of aspects, covering skills, education, and employability.

Employability support available through the Young Person’s Guarantee was delivered through Local Employability Partnerships, with Local Authorities acting as lead accountable body. Specific details on funding are not held by the Scottish Government, therefore requests for this information would need to be directed towards Local Authorities. Employability contacts for each local authority can be found on the Employability in Scotland website which can be accessed here: https://www.employabilityinscotland.com/local-employability-services/

Employability support for young people is now delivered through the No One Left Behind approach across Scotland including Edinburgh, as part of the long-term ambition to simplify the employability landscape for service users.